CHDI Foundation, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CHDI Foundation, Inc.
Further promising compounds will be explored after Bristol Myers Squibb exercised its option to enter an exclusive license for Evotec’s investigational EVT8683, generated by the German group’s iPSC platform as a potential treatment for neurodegenerative conditions.
Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
In a novel move to overcome the slowdown in outsourcing, small-molecule drug discovery company Evotec has bought asset manager Bionamics to more quickly progress assets originating in German academia.
- Academic and Research Institutions